204 related articles for article (PubMed ID: 33071706)
1. Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.
Li L; Li Y; Yang CH; Radford DC; Wang J; Janát-Amsbury M; Kopeček J; Yang J
Adv Funct Mater; 2020 Mar; 30(12):. PubMed ID: 33071706
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer.
Li L; Wang J; Radford DC; Kopeček J; Yang J
J Control Release; 2021 Apr; 332():652-659. PubMed ID: 33607175
[TBL] [Abstract][Full Text] [Related]
3. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity.
Yang S; Shim MK; Song S; Cho H; Choi J; Jeon SI; Kim WJ; Um W; Park JH; Yoon HY; Kim K
Biomaterials; 2022 Nov; 290():121841. PubMed ID: 36206664
[TBL] [Abstract][Full Text] [Related]
4. Dendronized polymer conjugates with amplified immunogenic cell death for oncolytic immunotherapy.
Li Y; Li L; Wang J; Radford DC; Gu Z; Kopeček J; Yang J
J Control Release; 2021 Jan; 329():1129-1138. PubMed ID: 33098912
[TBL] [Abstract][Full Text] [Related]
5. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
6. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
[TBL] [Abstract][Full Text] [Related]
7. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
[TBL] [Abstract][Full Text] [Related]
8. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
9. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V
Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051
[TBL] [Abstract][Full Text] [Related]
11. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
13. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
14. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
[TBL] [Abstract][Full Text] [Related]
16. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.
Yu Y; Li J; Song B; Ma Z; Zhang Y; Sun H; Wei X; Bai Y; Lu X; Zhang P; Zhang X
Biomaterials; 2022 Jan; 280():121312. PubMed ID: 34896861
[TBL] [Abstract][Full Text] [Related]
17. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
Zhou M; Luo C; Zhou Z; Li L; Huang Y
J Control Release; 2021 Jun; 334():248-262. PubMed ID: 33915224
[TBL] [Abstract][Full Text] [Related]
18. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
[TBL] [Abstract][Full Text] [Related]
20. Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma.
Tan X; Wang C; Zhou H; Zhang S; Liu X; Yang X; Liu W
J Nanobiotechnology; 2023 Jun; 21(1):183. PubMed ID: 37291573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
